Hong KongMay 12, 2026 /PRNewswire/ — Hong Kong Sanatorium & Medical Group (HKSH) and Siemens Healthineers, a global leader in medical technology, signed a cooperation agreement today at the “Asia Summit on Global Health.” The agreement establishes HKSH as Siemens Healthineers’ first Photon-Counting Computed Tomography Simulator (PCCT-Sim) Center of Excellence in Asia. In addition to being a research partner for Siemens Healthineers in PCCT-Sim technology, HKSH will now serve as a designated venue for industry training and observational demonstrations as a Center of Excellence. This collaboration marks HKSH’s foresight and innovation in advancing photon-counting technology and enhancing the precision of radiotherapy, medical diagnosis, and treatment planning, while solidifying Hong Kong’s leading position in cutting-edge clinical medical research.
Mr. David Li, Director of Li Shu Fan Medical Foundation, Chief Operating Officer of HKSH Medical Group, and Director of Hong Kong Sanatorium & Hospital (front left), and Mr. Sven Richard KOSTER, Senior Vice President of Greater China and Head of Imaging Diagnostics at Siemens Healthineers (front right), signed the cooperation agreement at the ‘Asia Summit on Global Health,’ witnessed by Ms. Sophia Chong, Assistant Executive Director of the Hong Kong Trade Development Council (back center), Mr. Chan Yuk Chuen, Head of Business Development at HKSH Medical Group (back left), and Mr. Yuen Wai Keung, Vice President of Hong Kong at Siemens Healthineers Greater China (back right). The agreement establishes HKSH as Siemens Healthineers’ first Photon-Counting Computed Tomography Simulator Center of Excellence in Asia.
HKSH Leverages Top-Tier Research Capabilities to Become Siemens Healthineers Center of Excellence
Mr. David Li, Director of Li Shu Fan Medical Foundation, Chief Operating Officer of HKSH Medical Group, and Director of Hong Kong Sanatorium & Hospital, stated: “HKSH is honored to become Siemens Healthineers’ first Center of Excellence in Asia. This fully recognizes our leading position in clinical experience and medical quality. Based on clinical data from Hong Kong, HKSH will participate in developing PCCT-Sim workflows and research protocols. Together with Siemens Healthineers, we will explore the limitless possibilities of this technology in diagnosis and treatment on the international stage, ultimately benefiting patients worldwide.”
Mr. Sven Richard KOSTER, Senior Vice President of Greater China and Head of Imaging Diagnostics at Siemens Healthineers, said: “Since signing the strategic cooperation agreement with HKSH last year, the teams at HKSH and Siemens Healthineers have rapidly integrated the innovative PCCT-Sim into actual clinical workflows, particularly in cancer treatment, where they have unified imaging diagnosis, treatment planning, and radiotherapy into a cohesive process. Therefore, as the first Center of Excellence in Asia, HKSH will serve as a benchmark for healthcare professionals, medical physicists, and scholars from around the world. True medical leadership lies not only in being the first to adopt new technologies but also in transforming innovation into clinical standards. This deepened cooperation further solidifies the mutual trust and shared vision between Siemens Healthineers and HKSH, reflecting our steadfast commitment to jointly pioneering the future of precision medicine.”
HKSH was among the first medical institutions globally to introduce PCCT-Sim last year and will add two more units within this year, making it the first medical institution worldwide to have the largest number of PCCT-Sim units. HKSH is actively conducting research projects on this technology and implementing it in clinical services for precision cancer treatment. This ultra-high-definition, faster, and low-radiation imaging technology aids in developing treatment plans and improving therapeutic outcomes. HKSH will fully apply it to clinical diagnosis and treatment planning, significantly enhancing patient well-being. Through this deepened collaboration, local clinical data will be transformed into a critical foundation for global technological advancement, further promoting the application standards of PCCT-Sim in precision cancer treatment worldwide.
The “Asia Summit on Global Health” is an annual event gathering top representatives from the global healthcare sector. The 2026 theme, “Driving Breakthroughs in Healthcare,” perfectly captures the essence of the collaboration between HKSH and Siemens Healthineers. By combining technological development with clinical practice, this partnership will lead precision medicine toward a new milestone. Mr. David Li and Mr. Sven Richard KOSTER signed the agreement on behalf of both parties at the event, witnessed by Ms. Sophia Chong, Assistant Executive Director of the Hong Kong Trade Development Council, Mr. Chan Yuk Chuen, Head of Business Development at HKSH Medical Group, and Mr. Yuen Wai Keung, Vice President of Hong Kong at Siemens Healthineers Greater China. This collaboration combines HKSH’s clinical insights with Siemens Healthineers’ research expertise to jointly drive medical technology innovation, ultimately elevating overall healthcare standards and benefiting a broad range of patients.
HKSH to Present PCCT-Sim Research Findings at International Conferences
HKSH is actively leveraging PCCT-Sim to further optimize proton therapy dose calculation and tumor target delineation. By closely integrating cutting-edge technologies like photon-counting CT with clinical needs, HKSH not only brings higher-quality medical services to patients in Hong Kong but also aims to set a new benchmark for the innovative application of global medical technology. Relevant clinical data and research findings will be presented at two major international radiotherapy conferences: the European Society for Radiotherapy and Oncology (ESTRO) meeting in Sweden in May and the Particle Therapy Co-Operative Group (PTCOG) annual meeting in France in June, contributing to global medical research.
PCCT-Sim uses cadmium telluride crystal detection technology to directly convert X-ray photons into electrical signals, providing unprecedented image detail and spectral information while reducing radiation dose by up to 70%. PCCT-Sim overcomes the limitations of conventional CT scans, such as insufficient contrast resolution, artifacts, and the inability to provide functional information. With superior spatial and contrast resolution, it produces ultra-high-definition images, enabling more precise delineation of tumors and surrounding healthy tissues.
In proton therapy applications, PCCT can more accurately calculate the position of the Bragg peak, reducing uncertainties in dose calculation and thereby improving treatment outcomes. In advanced radiotherapy techniques such as intensity-modulated or stereotactic radiotherapy, precise target delineation is crucial, especially for very small or structurally complex lesions. PCCT’s exceptional tissue differentiation capability minimizes errors in tumor region delineation, avoiding underdosing of the tumor or excessive radiation to surrounding healthy tissues, which could compromise treatment efficacy or increase the risk of side effects. This truly enables safer, more personalized precision cancer treatment.
HKSH Cancer Centre, benchmarked against world-class treatment standards, previously pioneered the introduction of the first proton therapy system in the Greater Bay Area in Hong Kong and continues to enhance the precision of proton therapy. As a top-tier radiotherapy modality, proton therapy requires extremely high precision to maximize treatment benefits while minimizing the risk of radiation side effects. Mr. David Li added: “To further reduce the number of proton therapy sessions and improve efficacy, ultra-precise imaging technology is the key cornerstone for minimizing treatment errors. Therefore, HKSH is fully committed to PCCT-Sim, this ultra-precise simulation positioning technology representing the future of CT scanning. PCCT-Sim will create a powerful synergy with proton therapy, driving cancer management to a higher level.”